Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 33.30M P/E - EPS this Y -26.70% Ern Qtrly Grth -
Income -27.2M Forward P/E -5.56 EPS next Y 16.80% 50D Avg Chg -1.00%
Sales 23.1M PEG - EPS past 5Y - 200D Avg Chg 12.00%
Dividend N/A Price/Book 0.84 EPS next 5Y - 52W High Chg -49.00%
Recommedations 2.00 Quick Ratio 2.14 Shares Outstanding 15.46M 52W Low Chg 72.00%
Insider Own 45.64% ROA -26.60% Shares Float 6.22M Beta 0.65
Inst Own 24.23% ROE -85.43% Shares Shorted/Prior 161.68K/171.98K Price 2.50
Gross Margin 56.81% Profit Margin -117.68% Avg. Volume 30,411 Target Price 6.00
Oper. Margin -240.11% Earnings Date Nov 14 Volume 18,307 Change 2.04%
About CASI Pharmaceuticals, Inc.

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. The company has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.

CASI Pharmaceuticals, Inc. News
11/17/24 CASI Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations
11/15/24 CASI Pharmaceuticals Announces Third Quarter 2024 Business and Financial Results
10/24/24 CASI Pharmaceuticals Receives CTA Approval From China's NMPA for CID-103 in Immune Thrombocytopenia
09/26/24 CASI Pharmaceuticals (NASDAQ:CASI) shareholders are still up 129% over 1 year despite pulling back 22% in the past week
09/04/24 CASI PHARMACEUTICALS TO PARTICIPATE IN THE 2024 H.C. WAINWRIGHT GLOBAL INVESTMENT CONFERENCE
08/16/24 CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2024 BUSINESS AND FINANCIAL RESULTS
07/19/24 CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS
07/08/24 CASI Pharmaceuticals announces appointment of Daniel Lang, MD as CFO and SVP
06/27/24 CASI Pharmaceuticals (CASI) Up on Buyout Offer for China Business
06/26/24 CASI Pharmaceuticals Announces Plan To Submit IND Application For CID-103, an Anti-CD 38 Antibody in Antibody-Mediated Rejection, and Receipt of a Non-Binding Proposal to Acquire Entire China Business of the Company
06/26/24 CASI Pharmaceuticals Announces $15 Million Private Placement Financing by Venrock Healthcare Capital Partners, Foresite Capital, Panacea Venture and Dr. Wei-Wu He
05/15/24 CASI Pharmaceuticals Receives FDA Clearance On The Investigational New Drug (IND) Application For CID-103 In Immune Thrombocytopenia (ITP)
05/14/24 CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2024 BUSINESS AND FINANCIAL RESULTS
04/24/24 Analysts Are Optimistic We'll See A Profit From CASI Pharmaceuticals, Inc. (NASDAQ:CASI)
03/28/24 CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2023 BUSINESS AND FINANCIAL RESULTS
03/05/24 CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In China
02/16/24 CASI PHARMACEUTICALS ANNOUNCES FIRST DOSING OF FOLOTYN® IN CHINA
12/18/23 CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Price Is Right But Growth Is Lacking After Shares Rocket 33%
CASI Chatroom

User Image Stocktwit1947 Posted - 1 day ago

$AGRI 🚀🚀💎🌱💰 $BTC.X $CASI $XRP.X https://qz.com/agriforce-growing-systems-ltd-agri-reports-earnings-1851703459

User Image Adammorocco Posted - 2 days ago

$CASI premium short squeeze candidate! $AMC $GME

User Image Adammorocco Posted - 3 days ago

$CASI only 100K stocks to short available! this is a prime #shortsqueeze candidate! $GME $AMC

User Image Adammorocco Posted - 3 days ago

$CASI only 100K stocks to short available! this is a prime #shortsqueeze candidate!

User Image Adammorocco Posted - 3 days ago

$CASI this keeps beating EPS and expected to grow 138% next year revenue! looks dirt cheap now and far away from its ATH… positioning here.

User Image MarketPlumber Posted - 6 days ago

$CASI 💩

User Image DonCorleone77 Posted - 6 days ago

$CASI Casi Pharmaceuticals reports Q3 EPS (55c) vs. (35c) last year Reports Q3 revenue $7.79M vs. $8.8M last year. Wei-Wu He, Chairman and CEO of CASI, said "The third quarter of 2024 marks a period of substantial progress for CASI as we continue to refine our company's strategic focus on the development for organ transplant rejection and autoimmune diseases. We just announced the Center for Drug Evaluation of China's National Medical Products Administration has approved our Clinical Trial Application for a phase 1/2 study of CID-103 in patients with chronic Immune Thrombocytopenia in China. This China study is part of the global study that was approved by the US FDA in May. Furthermore, we are making steady progress towards filing the Investigational New Drug application for Antibody-Mediated Rejection of renal allograft in the US."

User Image Stocksrockman Posted - 6 days ago

$ZONE This is the one News is coming No dilution $FENG hot $ptix very nice day $LUXH and $CASI are bullish

User Image TradeWithNaren Posted - 2 weeks ago

$XTIA after $BJDX join the room for free calls $CASI $HOLO $AGFY

User Image MrDaily Posted - 10/28/24

$CASI where does the buyout stand?

User Image Stocksrockman Posted - 10/26/24

$ATPC no dilution S1 filled Possible PR Trending $casi boom $FLGC bullish $Kuke and $husa spike

User Image BeatenDownBioBot Posted - 10/25/24

$CASI 3.5 years, still here BING BONG!!

User Image billythegoat1 Posted - 1 month ago

Check out this cool DPX video by $BVAXF. Great illustrations and educational for people who are not familiar with the technology $CASI $CYTH $OCX $AVNR https://x.com/biovaxys/status/1841242252238340246

User Image deesht Posted - 09/27/24

@PenkeTrading You mentioned $CASI 'oversold', worked well, stock went up yesterday. Thanks

User Image PenkeTrading Posted - 09/25/24

I found you an Oversold RSI (Relative Strength Index) on the daily chart of CASI Pharmaceuticals Inc. Is that bullish or bearish? $CASI #CASI #RsiOversold #NASDAQ

User Image MarketPlumber Posted - 09/24/24

$CASI dumping hard💩🗑

User Image Doozio Posted - 2 months ago

YO already know the sim is just trolling. So $casi is ready to go NOW that Pditty is behind bars during 🧠⏰♾️

User Image vu_jade Posted - 2 months ago

$CASI spec buy

User Image Doozio Posted - 2 months ago

$CASI chop chop huckleberries 🧠⏰

User Image John_WicKk Posted - 08/22/24

$CASI is this halted ? 0 volume for the day is very strange

User Image MinotaurKing Posted - 3 months ago

$CASI when is er?

User Image DonCorleone77 Posted - 3 months ago

$CASI I do not know the background. You will have to do your own DD: Casi Pharmaceuticals files to sell 3M ordinary shares for holders

User Image lecorb Posted - 3 months ago

$CASI Casi Pharmaceuticals (NASDAQ:CASI) filed a prospectus related to the offer and sale of 3,000,000 ordinary shares for holders.

User Image DonCorleone77 Posted - 3 months ago

$AMAT $HRB $MSGE $CINT $CASI Follow me for pre-market and after-hours movers every day: PRE-MARKET MOVERS: Currently Higher After Earnings: -- CI&T (CINT) up 20.3% -- MSG Entertainment (MSGE) up 6.8% -- Casi Pharmaceuticals (CASI) up 5.2% -- Sigma Lithium (SGML) up 3.0% -- AIM ImmunoTech (AIM) up 3.5% -- Kandi Technologies (KNDI) up 3.9% -- Sol-Gel Technologies (SLGL) up 2.4% -- H&R Block (HRB) up 8.0% Currently Also Higher: -- MediWound (MDWD) up 1.5% after announces FDA approval for pediatric indication for NexoBri Currently Lower After Earnings: -- Shimmick (SHIM) down 28.4% -- Applied Materials (AMAT) down 3.0%

User Image epsguid Posted - 3 months ago

$CASI reported a loss of $0.52, consensus was ($0.63) via @eWhispers #epsbeat http://eps.sh/d/casi

User Image Stock_Titan Posted - 3 months ago

$CASI CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2024 BUSINESS AND FINANCIAL RESULTS https://www.stocktitan.net/news/CASI/casi-pharmaceuticals-announces-second-quarter-2024-business-and-5ka7pib6uozz.html

User Image NVDAMillionaire Posted - 3 months ago

$CASI CASI Pharmaceuticals Faces Headwinds, but Promising Pipeline Offers Hope http://beyondspx.com/2024/08/01/casi-pharmaceuticals-faces-headwinds-but-promising-pipeline-offers-hope/

User Image klr500 Posted - 07/31/24

$CASI a giant 🚀 price target $12

User Image MrDaily Posted - 07/31/24

$CASI all the momentum and positive news. Primed to fly

User Image klr500 Posted - 07/30/24

$CASI 🚀

Analyst Ratings
HC Wainwright & Co. Buy May 15, 24
HC Wainwright & Co. Buy Nov 15, 23
HC Wainwright & Co. Buy Aug 14, 23
HC Wainwright & Co. Buy May 22, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Huang James Director Director Sep 06 Buy 4.06 55,573 225,626 371,517 09/08/22
Huang James Director Director Aug 31 Buy 3.74 37,196 139,113 315,944 09/02/22
Huang James Director Director Aug 24 Buy 3.75 44,527 166,976 278,748 08/26/22
Huang James Director Director Aug 19 Buy 3.41 234,221 798,694 234,221 08/23/22